August 15, 2020
New Focus on ADT in Prostate Cancer GuidelineBookmarkGeorge Lundberg, MD
Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes:
Hormone therapy has been a mainstay in the treatment of metastatic prostate cancer. But, until now, guidelines have been short on detail. This news story outlines 38 approved additions to guidelines.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
June 18, 2015 Emma Shtivelman, PhD
This year’s American Society of Clinical Oncology (ASCO) annual meeting was short on any truly exciting developments in prostate cancer treatment. In stark contrast to other cancers, such as lung, breast, kidney, and melanoma, there were no reports of note… Read more »
February 17, 2015 Emma Shtivelman, PhD
Androgen deprivation therapy (ADT) has long been a mainstay in the management of prostate cancer. Indeed, the vast majority of prostate cancers depend on androgens (hormones like testosterone) for their growth. Lowering testosterone levels with ADT is a reasonable approach.… Read more »